Series A Round

Avammune Therapeutics is a biopharmaceutical company focused on small molecule drug discovery and development, specifically targeting modulators of the innate immune system to treat cancer and autoimmune disorders. The company aims to advance innovative therapies that harness the body's innate immune response to combat diseases. With a strong emphasis on research and development, Avammune is committed to bringing transformative therapies to market that can significantly improve patient outcomes. The funding will be utilized to accelerate the development of their lead candidates and expand their research capabilities. The company also plans to enhance its clinical trial infrastructure and explore partnerships for further development. Avammune Therapeutics is headquartered in India and is positioned to make significant contributions to the healthtech landscape.